Arcellx (ACLX) to Release Earnings on Thursday

Key Points

• Arcellx (ACLX) is set to release its Q2 2025 earnings results on August 14, with analysts anticipating a loss of $1.03 per share.
• The company's last earnings report showed a loss of $1.13 per share, missing analyst estimates, alongside a revenue of only $8.13 million compared to predictions of $19.51 million.
• Arcellx has recently attracted institutional investors, with 96.03% of its stock currently owned by these entities, indicating strong interest in the company.

Arcellx (NASDAQ:ACLX - Get Free Report) is anticipated to release its Q2 2025 earnings data before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($1.03) per share and revenue of $16.76 million for the quarter.

Arcellx (NASDAQ:ACLX - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.03) by $0.09. Arcellx had a negative net margin of 211.46% and a negative return on equity of 35.27%. The business had revenue of $7.55 million during the quarter, compared to the consensus estimate of $16.76 million. On average, analysts expect Arcellx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Arcellx Price Performance

Shares of NASDAQ ACLX traded down $0.65 during trading on Friday, hitting $70.50. The stock had a trading volume of 867,672 shares, compared to its average volume of 662,037. The firm has a fifty day moving average of $67.38 and a two-hundred day moving average of $65.18. Arcellx has a 12 month low of $47.86 and a 12 month high of $107.37. The company has a market capitalization of $3.89 billion, a PE ratio of -23.58 and a beta of 0.28.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on ACLX shares. Scotiabank raised their price target on Arcellx from $93.00 to $133.00 and gave the company a "sector outperform" rating in a research report on Thursday, July 31st. HC Wainwright reiterated a "buy" rating and issued a $115.00 price target on shares of Arcellx in a report on Monday, June 16th. Citigroup began coverage on shares of Arcellx in a research report on Tuesday, June 17th. They issued a "buy" rating and a $110.00 target price for the company. Finally, Cantor Fitzgerald upgraded Arcellx to a "strong-buy" rating in a report on Monday. Thirteen investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $114.31.

Insiders Place Their Bets

In related news, Director Kavita Patel sold 1,500 shares of the firm's stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $67.36, for a total transaction of $101,040.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 8.35% of the company's stock.

Hedge Funds Weigh In On Arcellx

Hedge funds and other institutional investors have recently modified their holdings of the company. Intech Investment Management LLC grew its stake in Arcellx by 27.7% during the 1st quarter. Intech Investment Management LLC now owns 21,967 shares of the company's stock valued at $1,441,000 after acquiring an additional 4,760 shares in the last quarter. Empowered Funds LLC bought a new stake in shares of Arcellx during the first quarter worth approximately $1,768,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Arcellx by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,753 shares of the company's stock valued at $1,893,000 after acquiring an additional 1,390 shares during the period. Institutional investors and hedge funds own 96.03% of the company's stock.

Arcellx Company Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).